WGS
GeneDx Holdings Corp.141.72
-8.89-5.9%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
4.10BP/E (TTM)
1288.36Basic EPS (TTM)
0.11Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
GeneDx appoints AI expert director
GeneDx Holdings Corp. appointed Thomas Fuchs, Dr.sc., as a Class I director effective September 17, 2025, expanding its board from seven to eight members. Fuchs, SVP and Chief AI Officer at Eli Lilly, brings deep expertise in AI for drug discovery and clinical trials from prior roles at Mount Sinai and Memorial Sloan Kettering. He receives a $420,000 initial restricted stock unit grant vesting over three years. This addition bolsters GeneDx's AI-driven diagnostics strategy.
10-Q
Q2 FY2025 results
GeneDx swung to an operating profit of $9.0M in Q2 FY2025 ended June 30, 2025, up from a $10.6M loss a year earlier, as revenue jumped 46% y/y to $102.7M on 28% higher exome and genome test volumes and better reimbursement rates, while gross margin expanded to 69.0% from 60.9%. Diagnostic testing drove the surge, with other revenue tripling to $2.9M including $0.9M from the May 2025 Fabric Genomics acquisition for $33.5M cash plus $3.4M contingent consideration, recognizing $12.9M goodwill and $25.5M finite-lived intangibles amortized over 9-15 years. Operating cash flow turned positive at $20.6M for the half-year, bolstering $74.1M cash against $55.2M total debt including a $50M Perceptive term loan due 2028 at Term SOFR +7.5%. Yet regulatory shifts on lab-developed tests could tighten oversight.
8-K
GeneDx Q2 revenue jumps 49%
GeneDx reported Q2 2025 revenues of $102.7 million, up 49% year-over-year, with exome and genome tests surging 69% to $85.9 million on 28% higher volume. Adjusted gross margin hit 71%, fueling $15.0 million in adjusted net income—fourth straight profitable quarter. The company raised full-year revenue guidance to $400-$415 million, spotlighting AAP's endorsement of exome/genome as first-line pediatric testing. Fabric Genomics acquisition bolsters global reach, yet regulatory shifts pose risks.
IPO
Website
Employees
Sector
Industry
APDN
Applied DNA Sciences, Inc.
5.62+1.35
DGX
Quest Diagnostics Incorporated
178.66-5.45
GH
Guardant Health, Inc.
100.00-2.67
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
LDDD
LONGDUODUO CO LTD.
0.59+0.00
MEHCQ
CHROME HLDG CO
3.50+0.00
NEO
NeoGenomics, Inc.
11.67-0.25
PRE
Prenetics Global Limited
16.58+1.95
QGEN
Qiagen N.V.
45.01-0.43